Published in final edited form as:

Antiviral Res. 2011 June ; 90(3): 183–186. doi:10.1016/j.antiviral.2011.03.184.

Human Cytomegalovirus Kinetics Following Institution of Artesunate after Hematopoietic Stem Cell Transplantation

Dana G. Wolf¹, Avichai Shimoni², Igor B Resnick³, Thomas Stamminger⁴, Avidan U. Neumann⁵, Sunwen Chou⁶, Thomas Efferth⁷, Orit Caplan¹, Jessica Rose⁵, Arnon Nagler^{2,*}, and Manfred Marschall^{4,*}

¹Clinical Virology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel

²Division of Hematology and Bone Marrow transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel

³Bone Marrow transplantation and cancer Immunotherapy Department, Hadassah Hebrew University Medical Center, Jerusalem, Israel

⁴Virological Institute of the University Hospital Erlangen, University of Erlangen-Nuremberg, Germany

⁵Bar-Ilan University, Ramat-Gan, Israel

⁶VA Medical Center and Oregon Health and Science University, Portland, Oregon

⁷German Cancer Research Center, Heidelberg, Germany

Abstract

The anti-malaria drug artesunate has been shown to be an effective inhibitor of cytomegalovirus (CMV) *in vitro*, in an experimental animal model, and in a recent single-case clinical use. In this first case-series of 6 stem cell transplant recipients who received preemptive artesunate treatment for CMV infection, we have examined the viral kinetics following institution of artesunate, and employed first-phase viral kinetics studies to calculate its antiviral effectiveness. Two patients demonstrated a rapid 0.8-2.1 log viral load decline by 7 days, with a viral decay half-life of 0.9 -1.9d. Four patients demonstrated a continued yet stalled viral growth slope during treatment. No adverse events were noted in treatment courses of up to 28 days. Overall, a divergent antiviral efficacy was revealed, ranging from 43% to 90%, which appeared to be primarily dependent on the virus baseline growth dynamics. Further dose escalation studies are needed to examine the role of artesunate in the treatment of CMV infection in the transplantation setting.

Keywords

cytomegalovirus; artesunate; antiviral drugs; viral kinetics

© 2011 Elsevier B.V. All rights reserved.

Corresponding author: Dana G. Wolf, M.D., Clinical Virology Unit, Dept. of Clinical Microbiology & Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel, 91120, Phone:972-2-6777890, Fax:972-2-6427921, dana.wolf@ekmd.huji.ac.il.

*AN and MM contributed equally to the work

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1.1. Despite the availability of effective antiviral therapy and reliable diagnostic assays, cytomegalovirus (CMV) has remained a significant complication after hematopoietic stem cell transplantation (HSCT) (Boeckh and Ljungman, 2009).

All currently available anti-CMV drugs, including ganciclovir, foscarnet, and cidofovir, target the viral DNA polymerase. Their use is limited by toxicity, low oral bioavailability (with the exception of the oral prodrug valganciclovir), and drug resistance (Boeckh and Ljungman, 2009; Lurain and Chou, 2010). These limitations, along with the epidemiological shift of CMV infection, requiring repeated and prolonged treatment courses, create an increasing need for new, effective, and better-tolerated antiviral drugs.

The benzimidazole L-riboside maribavir which targets the UL97 kinase has held promise as an alternative treatment for CMV infection (Winston et al., 2008). However, recent results from a phase III study have not revealed a significant impact on the rate of CMV disease following HSCT.

1.1.1. Recently, the anti-malaria drug artesunate has been shown to be an effective inhibitor of human CMV *in vitro* and in an experimental animal model (Efferth et al., 2002; Efferth et al., 2008; Kaptein et al., 2006; Schnepf et al., 2010). Importantly, the extensive use of artesunate in malaria patients has not been associated with significant adverse effects (Efferth et al., 2008). These characteristics raise the possibility that artesunate could represent a safe therapeutic option for CMV infection in immunocompromised patients.

We have recently described the successful clinical use of artesunate for the treatment of CMV in a single patient who developed drug-resistant infection during preemptive antiviral therapy after HSCT (Shapira et al., 2008).

1.1.2. Here we report the first case-series of 6 HSCT recipients who received preemptive artesunate treatment for CMV infection; utilizing frequent viral load monitoring, we have examined the viral kinetics following institution of artesunate, and further employed first-phase viral kinetics studies to determine its antiviral effectiveness.

1.1.3. Of the 6 patients, one (Table 1, Patient #1) received preemptive artesunate treatment on a compassionate basis due to increasing viral load with emergence of multi-drug-resistant L776M DNA polymerase (*pol*) mutant (Shapira et al., 2008). Five patients (Table 1, Patients #2-6) were enrolled in a pilot study aimed to evaluate the safety and efficacy of artesunate in preemptive treatment of CMV infection in HSCT recipients > 18 years, who had detectable CMV DNA with ≥ 2000 DNA copies/ml. Eligible patients in this study received preemptive treatment with oral artesunate (Dafra Pharma, Belgium; 200 mg $\times$ 2/d for one day, followed by 100 mg $\times$ 1/d for 28 days). CMV DNA load was determined on days 0, 3, 7, 14, 21, 28 of treatment by real-time PCR assay as described (Boeckh et al., 2004). Artesunate was discontinued upon lack of clear virological response (defined as viral load increase or decrease by < 0.5 log DNA copies/ml) on days 7, 14, 21. These strict criteria were employed to prevent deterioration during treatment. (For more details of the study design, see ClinicalTrials.gov NCT00284687; The study was approved by the Institutional and National Ethics Committees and performed according to the Declaration of Helsinki, Good Clinical Practice guidelines, and the Human-Experimentation Guidelines of the Israeli Ministry of Health. All participants gave written informed consent).

1.1.4. The viral doubling time and decay half life ($T_{1/2}$) were calculated on the basis of the best-fit curve by use of the equation $(\ln 2)/a$, where “a” is the logarithmic slope (Emery et al., 1999). The antiviral effectiveness of artesunate (ϵ) was calculated in 2 ways: For patients with an early decline in viremia, we used the magnitude of the first-phase viral decline (D in log₁₀ base) in the equation $\epsilon = 1 - 10^{-D}$ (Neumann et al., 1998). For patients with delayed

virological response we used the equation $\varepsilon = 1 - S_A/S_0$ where “ S_A ” and “ S_0 ” represent the exponential viral growth slopes immediately after and before the initiation of treatment, respectively, according to the model developed by Neumann et al. for viral kinetics (Neumann et al., 1998).

1.1.5. Two patients (Patients #1 and #2; Table 1 and Fig. 1) successfully completed 28 days of artesunate treatment. These patients exhibited a rapid decline in viral load, with 0.8-2.1 log decline by 7 days of treatment and a viral $T_{1/2}$ of 0.9 -1.9 d (see Table 1). These viral decay kinetics are consistent with those previously reported for ganciclovir and foscarnet (Emery et al., 1999). Based on the first-phase viral decline, a high antiviral effectiveness (82% - 90%) was calculated.

In the four remaining patients (patients #3-6), artesunate was discontinued at 7 days of treatment, in accordance with the study criteria, due to the development of CMV disease (patient #3) or lack of clear virological response (patients #4-6). While no viral load decline was observed in these patients by 7 days of artesunate treatment, all four demonstrated a stalled viral growth slope during treatment (S_A) when compared to baseline growth rate (S_0) (see Table 1, Fig. 1). These viral dynamics revealed some, albeit variable and limited antiviral effectiveness, ranging from 43% to 84% in patients #3-6 (Table 1). Notably, three of these patients (patients #4-6) rapidly responded to ganciclovir (Fig. 1), with a 1.4-1.8 log decline at day 7 of ganciclovir treatment – suggesting a lower antiviral efficacy of artesunate, in its current dosing regimen, when compared to ganciclovir. However, it is important to interpret these findings with caution, as an initial lag phase of virologic response has been also reported in high-risk patients receiving ganciclovir (Buyck, Griffiths, and Emery, 2010; Nichols et al., 2001). Thus, the small number of patients, and the early discontinuation of artesunate in 4 of the 6 patients preclude conclusions regarding its relative antiviral efficacy in heavily immunosuppressed patients.

1.1.6. We sought to elucidate the basis for the enhanced response to artesunate in patients #1 and #2 when compared to patients #3-6; The rapid viral load decrease in patient #2 could be attributed to an earlier reconstitution of the host immune response following autologous HSCT, along with a low baseline viral load (Table 1), a well-known predictor of viral eradication. Yet, these factors could not account for the effective block of viral replication by artesunate in patient #1, who had received a T-cell depleted haploidentical HSCT, and exhibited a high baseline viral load of $>10^6$ copies/ml. Limited analysis of artesunate and dihydroartemisinin concentrations in available plasma samples by the liquid chromatography- mass spectrometry method (Van Quekelberghe et al., 2008), did not show significant differences between the patients (data not shown), and thus could not explain the different response rates. Importantly, patient #1 harbored a mutant virus containing a *pol* L776M substitution, previously shown to confer a slight replication defect in cell culture (Shapira et al., 2008). Furthermore, analysis of the mutant-virus baseline growth kinetics revealed a slow *in vivo* growth rate, with a prolonged doubling time of 7.6 days (Table 1). Thus, the attenuated growth of the mutant could have accounted for the enhanced response to artesunate in this case.

To further examine if the L776M *pol* mutation confirmed increased artesunate susceptibility, we compared the artesunate IC₅₀ of a recombinant mutant strain, containing the L776M mutation and a wild type control virus, using a secreted alkaline phosphatase (SEAP) activity assay as described (Scott et al., 2007; Shapira et al., 2008). The artesunate IC₅₀ of the mutant ($1.68 \pm 0.30 \mu\text{M}$) was slightly lower than that of the wild type ($2.53 \pm 0.96 \mu\text{M}$), as revealed in 14 replicate assays spread over 4 setup dates. Further testing with artemisinin demonstrated similar trend for increased susceptibility of the mutant (IC₅₀ $14.6 \pm 4.1 \mu\text{M}$ versus $35.3 \pm 11.1 \mu\text{M}$, in 4 to 7 replicates over 2 setup dates). These findings may be

relevant towards the future use of artesunate in patients with drug-resistant CMV mutants, especially those demonstrating reduced fitness. Experiments are currently underway to examine its activity against various drug-sensitive and drug-resistant clinical isolates.

1.1.7. In view of the limited and diverse response to artesunate as demonstrated herein, a prophylactic rather than preemptive treatment study design, and a dose escalation study with close pharmacokinetic monitoring should be considered in future trials. The safety of this approach is supported by the low rate of toxicity reported for artesunate (Efferth et al., 2008), and the lack of adverse events in the 6 HSCT recipients treated over 7-56 days. We believe that the favorable safety profile of artesunate, along with its unique mechanism of antiviral activity, involving inhibition of early replication steps (Efferth et al., 2002; Efferth et al., 2008; Kaptein et al., 2006), will make it an attractive candidate for combination antiviral drug therapy. In this regard, artesunate, has been shown to exert an additive *in vitro* antiviral effect when combined with any of the currently available anti-CMV drugs (Efferth et al., 2008; Kaptein et al., 2006). Combined ganciclovir-artesunate treatment could potentially allow for reduced dosage of ganciclovir and thus limit its bone marrow toxicity.

1.1.8. In conclusion, these first-phase viral kinetics studies in 6 HSCT recipients who received preemptive artesunate treatment revealed a divergent antiviral efficacy of artesunate, ranging from 43% to 90%, which appeared to be primarily dependent on the virus baseline growth dynamics. Further dose escalation studies are needed to examine the role of artesunate in the treatment of CMV infection in the transplantation setting.

Acknowledgments

This work was supported by grants from the Israeli Ministry of Health and the Israel Science Foundation (D.G.W.), the HHV-6 Foundation (M.M.), the Bayerische Forschungsförderung (M.M., T.S.), and NIH grant AI39938 (S.C.).

Artesunate tablets were generously provided by Dafra Pharma, Belgium.

The funding sources had no involvement in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.

References

- Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, Corey L. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. *J Clin Microbiol.* 2004; 42(3):1142–8. [PubMed: 15004066]
- Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. *Blood.* 2009; 113(23):5711–9. [PubMed: 19299333]
- Buyck HC, Griffiths PD, Emery VC. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy. *J Clin Virol.* 2010; 49(1):32–6. [PubMed: 20667769]
- Efferth T, Marschall M, Wang X, Huang SM, Hauber I, Olbrich A, Kronschnabl M, Stamminger T, Huang ES. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. *J Mol Med.* 2002; 80(4):233–42. [PubMed: 11976732]
- Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. The antiviral activities of artemisinin and artesunate. *Clin Infect Dis.* 2008; 47(6):804–11. [PubMed: 18699744]
- Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. *J Exp Med.* 1999; 190(2):177–82. [PubMed: 10432281]
- Kaptein SJ, Efferth T, Leis M, Rechter S, Auerochs S, Kalmer M, Bruggeman CA, Vink C, Stamminger T, Marschall M. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. *Antiviral Res.* 2006; 69(2):60–9. [PubMed: 16325931]
- Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. *Clin Microbiol Rev.* 2010; 23(4):689–712. [PubMed: 20930070]

- Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science*. 1998; 282(5386): 103–7. [PubMed: 9756471]
- Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, Davis C, Boeckh M. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. *Blood*. 2001; 97(4): 867–74. [PubMed: 11159510]
- Schnepf N, Corvo J, Pors MJ, Mazon MC. Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocytoma cells. *Antiviral Res*. 2010
- Scott GM, Weinberg A, Rawlinson WD, Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. *Antimicrob Agents Chemother*. 2007; 51(1):89–94. [PubMed: 17043128]
- Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stamminger T, Caplan O, Saleh N, Efferth T, Marschall M, Wolf DG. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. *Clin Infect Dis*. 2008; 46(9):1455–7. [PubMed: 18419454]
- Van Quekelberghe SA, Soomro SA, Cordonnier JA, Jansen FH. Optimization of an LC-MS method for the determination of artesunate and dihydroartemisinin plasma levels using liquid-liquid extraction. *J Anal Toxicol*. 2008; 32(2):133–9. [PubMed: 18334096]
- Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N, Klein J, Sprague K, Villano SA, Boeckh M. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. *Blood*. 2008; 111(11):5403–10. [PubMed: 18285548]

Figure 1. CMV DNA load kinetics and antiviral treatment in HSCT recipients receiving preemptive artesunate treatment
Y axis values, log DNA copies/ml; X axis values, days after HSCT; arrow, time of disease development; ART, artesunate; GCV, ganciclovir; CDV, cidofovir; FOS, foscarnet; Maint., maintenance treatment.

Table 1
Demographic, clinical, and virological characteristics of HSCT recipients receiving preemptive artesunate treatment

Pt #	Gender / age, y	Underlying disease	Type of HSCT	Time of viremia post HSCT, d	Baseline Viral load, (copies/ml) / DT (d) / S ₀	viral load kinetics at 7d of artesunate treatment	Calculated antiviral effectiveness (e) ^a	Artesunate treatment outcome	Clinical & virological outcome following treatment ^b
1 ^c	M / 12	X-linked adrenoleuk-odystrophy	Haploidentical T-cell-depleted	147; 357	1.15 × 10 ⁶ / 32,500 / 7.6	1.7-2.1 log decline; T _{1/2} 0.9 -1.9 d; D 0.98	90%	Completed 56 d (2 treatment courses)	Asymptomatic; no rebound viremia for 76d
2	F / 66	Diffuse large B cell lymphoma	Autologous	28	2,500 / 1.8	0.8 log decline; T _{1/2} 1.8 d; D 0.75	82%	Completed 28 d	Asymptomatic; no rebound viremia for 1 y
3	M / 42	Acute lymphocytic leukemia	Mismatched	90	50,000 / 1.4 / 0.56	Stabilization; S _A 0.25	57%	Discontinued at 7d	CMV disease; Continued deterioration with foscarnet
4	M / 65	Acute myelocytic leukemia	Matched unrelated	81	24,000 / 1.8 / 0.39	Stabilization; S _A 0.06	84%	Discontinued at 7d	Asymptomatic; Rapid response to ganciclovir
5	M / 46	Acute myelocytic leukemia	haploidentical non-T-cell-depleted	35	12,400 / 0.98 / 0.71	0.86 log increase; S _A 0.28	60%	discontinued at 7d	Asymptomatic; Rapid response to ganciclovir
6	F / 52	Acute myelocytic leukemia	Matched unrelated	34	12,000 / 1.3 / 0.52	0.65 log increase; S _A 0.30	43%	Discontinued at 7d	Asymptomatic; Rapid response to ganciclovir

DT indicates doubling time; S₀ and S_A represent the exponential viral growth slopes before and immediately after the initiation of artesunate treatment (relevant for patients #3-6); T_{1/2} indicates viral decay half life; D represents the magnitude of the first-phase viral decline in log₁₀ base (relevant for patients #1,2)

^aCalculated as indicated in "Patients and Methods" section: for patients #1,2, $\epsilon = 1 - 10^{-D}$, for patients #3-6, $\epsilon = 1 - S_A/S_0$

^bFollowing completion or discontinuation of artesunate treatment.

^cPatient 1 had received 2 courses of preemptive artesunate on a compassionate basis as previously reported (7).